(Total Views: 498)
Posted On: 01/21/2020 9:04:30 PM
Post# of 153778
Thank You Trding,
Very useful information. As I understand, we have compassionate use approval for Pancreatic and Liver and these are as well in the basket trial proposal.
For many reasons our CCR5 antagonist (Leronlimab) has proven superior to Maraviroc, so this results bear very well for Leronlimab in that confirms that CCR5 antagonist indeed help with this condition(s).
We need some funding to start carrying out experiments as soon as feasible for Pancreatic and Liver cancers. I am very optimistic in that the results will be superior to those of Pfizer.
And, remember, Maraviroc can cause serious, life-threatening side effects. These include (paradoxically) liver problems, heart problems (including heart attack), skin reactions, and allergic reactions.
Very useful information. As I understand, we have compassionate use approval for Pancreatic and Liver and these are as well in the basket trial proposal.
For many reasons our CCR5 antagonist (Leronlimab) has proven superior to Maraviroc, so this results bear very well for Leronlimab in that confirms that CCR5 antagonist indeed help with this condition(s).
We need some funding to start carrying out experiments as soon as feasible for Pancreatic and Liver cancers. I am very optimistic in that the results will be superior to those of Pfizer.
And, remember, Maraviroc can cause serious, life-threatening side effects. These include (paradoxically) liver problems, heart problems (including heart attack), skin reactions, and allergic reactions.
(3)
(0)
